


## Claims:

1. A compound of Formula I, or a salt, solvate, or hydrate thereof



5 wherein

- $R^1$ ,  $R^2$  and  $R^3$  are each independently selected from H, OH,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkylCO<sub>2</sub>, NH<sub>2</sub>, NH- $C_{1-6}$ alkyl, N( $C_{1-6}$ alkyl)( $C_{1-6}$ alkyl),  $C_{1-6}$ alkyl(C=O)NH,  $C_{1-6}$ alkyl(C=O)N( $C_{1-6}$ alkyl), SH, S- $C_{1-6}$ alkyl, NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> and halo;
- $R^4$  is unsubstituted Ar, or Ar substituted with 1-4 substituents, independently selected
- 10 from  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, and halo;
- X is selected from (CH<sub>2</sub>CH<sub>2</sub>O)<sub>n</sub> and (CH<sub>2</sub>)<sub>n</sub>, and
- $n = 1-4$ .

2. The compound according to claim 1, wherein
- $R^1$ ,  $R^2$  and  $R^3$  are each independently selected from H, OH,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,
- 15  $C_{1-4}$ alkylCO<sub>2</sub>, NH<sub>2</sub>, NH- $C_{1-4}$ alkyl, N( $C_{1-4}$ alkyl)( $C_{1-4}$ alkyl),  $C_{1-4}$ alkyl(C=O)NH,  $C_{1-4}$ alkyl(C=O)N( $C_{1-4}$ alkyl), NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, and halo;
- $R^4$  is  $C_{1-6}$ alkyl,
- X is (CH<sub>2</sub>CH<sub>2</sub>O)<sub>n</sub>, and
- $n = 1-4$ .

- 20 3. The compound according to claim 1 or 2, wherein  $R^1$ ,  $R^2$ , and  $R^3$  are each independently selected from H, OH,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $C_{1-4}$ alkyl(CO)O, NH<sub>2</sub>, NH- $C_{1-4}$ alkyl, N( $C_{1-4}$ alkyl)( $C_{1-4}$ alkyl),  $C_{1-4}$ alkyl(C=O)NH,  $C_{1-4}$ alkyl(C=O)N( $C_{1-4}$ alkyl), NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, and halo.

4. The compound according to claim 3, wherein  $R^1$ ,  $R^2$  and  $R^3$  are each
- 25 independently selected from H, OH, OCH<sub>3</sub>, CH<sub>3</sub>CO<sub>2</sub>, NH<sub>2</sub>, N(CH<sub>3</sub>)<sub>2</sub>, CH<sub>3</sub>CONH, and NO<sub>2</sub>.

5. The compound according to claim 4, wherein  $R^1$ ,  $R^2$ , and  $R^3$  are each independently selected from H, OH, and OCH<sub>3</sub>.


6. The compound according to claim 1, wherein R<sup>4</sup> is unsubstituted Ar.
7. The compound according to claim 6, wherein R<sup>4</sup> is phenyl.
8. The compound according to claim 2, wherein R<sup>4</sup> is methyl or ethyl.
9. The compound according to claim 8, wherein R<sup>4</sup> is methyl.
- 5 10. The compound according to claim 9, wherein n is 2-3.
11. The compound according to claim 10, wherein n is 3.
12. A compound selected from:  
2-Cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-penta-2E,4E-dienoic acid benzyl ester  
(CRIX-38)  
10 2-Cyano-5-(3,4-dihydroxyphenyl)-penta-2E,4E-dienoic acid benzyl ester (CRIX-39)  
2-Cyano-5-(3,4-dihydroxyphenyl)-penta-2E,4E-dienoic acid 2-[2-(2-methoxyethoxy)ethoxy] ethyl ester (CRIV-42)  
2-Cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-penta-2E,4E-dienoic acid 2-[2-(2-methoxyethoxy)ethoxy]ethyl ester (CRIV-46); and  
15 2-Cyano-5-(4-hydroxy-3-methoxyphenyl)-penta-2E,4E-dienoic acid benzyl ester  
(CRIX-79).
13. A composition comprising a compound according to any one of claims 1 to 12 in admixture with a pharmaceutically acceptable diluent or carrier.
14. A use of a compound according to any of claims 1-12, and/or a composition  
20 according to claim 13, to prepare a medicament to modulate cell proliferation.
15. The use according to claim 14, for inhibiting cell proliferation.
16. The use according to claim 15, wherein the cell is a malignant hematopoietic cell.

17. A method of modulating cell proliferation comprising administering an effective amount of a compound according to any of claims 1-12, and/or a composition according to claim 13, to a cell or animal in need thereof.

18. The method according to claim 17, for inhibiting cell proliferation.

5 19. The method according to claim 18 wherein the cell is a malignant hematopoietic cell.

20. A compound of Formula III, or a salt, solvate, or hydrate thereof:



wherein

10 R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each independently selected from H, OH, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylCO<sub>2</sub>, NH<sub>2</sub>, NH-C<sub>1-6</sub>alkyl, N(C<sub>1-6</sub>alkyl)(C<sub>1-6</sub>alkyl), C<sub>1-6</sub>alkyl(C=O)NH, C<sub>1-6</sub>alkyl(C=O)N(C<sub>1-6</sub>alkyl), SH, S-C<sub>1-6</sub>alkyl, NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, and halo; and R<sup>4</sup> is selected from C<sub>1-6</sub>alkyl, phenyl and pyridyl, wherein phenyl and pyridyl are unsubstituted or substituted with 1-4 substituents, independently selected from

15 C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy and halo, with the provisos that when R<sup>1</sup> and R<sup>3</sup> are both H and R<sup>4</sup> is unsubstituted phenyl, R<sup>2</sup> is not H, Cl, or OCH<sub>3</sub>; when R<sup>1</sup> and R<sup>2</sup> are both H and R<sup>4</sup> is unsubstituted phenyl, R<sup>3</sup> is not NO<sub>2</sub>; and when R<sup>1</sup> and R<sup>3</sup> are both H and R<sup>4</sup> is CH<sub>3</sub>, R<sup>2</sup> is not N(CH<sub>3</sub>)<sub>2</sub>.

21. The compound according to claim 1, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each


20 independently selected from H, OH, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylCO<sub>2</sub>, NH<sub>2</sub>, NH-C<sub>1-4</sub>alkyl, N(C<sub>1-4</sub>alkyl)(C<sub>1-4</sub>alkyl), C<sub>1-4</sub>alkyl(C=O)NH, C<sub>1-4</sub>alkyl(C=O)N(C<sub>1-4</sub>alkyl), NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, and halo.

22. The compound according to claim 21, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each independently selected from H, OH, OCH<sub>3</sub>, CH<sub>3</sub>CO<sub>2</sub>, NH<sub>2</sub>, N(CH<sub>3</sub>)<sub>2</sub>, CH<sub>3</sub>CONH, and NO<sub>2</sub>.

25 23. The compound according to claim 20, wherein R<sup>4</sup> is selected from C<sub>1-4</sub>alkyl, phenyl, and pyridyl.

24. The compound according to claim 23, wherein R<sup>4</sup> is selected from CH<sub>3</sub> and phenyl.
25. The compound according to claim 24, wherein R<sup>4</sup> is unsubstituted phenyl.
26. The compound according to claim 20, wherein phenyl and pyridyl are  
5 unsubstituted or substituted with 1-3 substituents, independently selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, and halo.
27. The compound according to claim 24, wherein phenyl is unsubstituted or substituted with 1-2 substituents, independently selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, and halo.
- 10 28. The compound according to claim 20, wherein at least one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is OH while R<sup>4</sup> is selected from unsubstituted phenyl and phenyl substituted with 1-4 substituents, independently selected from C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, and halo.
29. A compound selected from:
- 2-Benzenesulfonyl-5-(3,4-dihydroxyphenyl)-penta-2E,4E-dienenitrile (CRVIII-33),  
15 2-Benzenesulfonyl-5-(4-hydroxy-3,5-dimethoxyphenyl)-penta-2E,4E-dienenitrile (CRVIII-34),  
2-Benzenesulfonyl-5-(4-nitrophenyl)-penta-2E,4E-dienenitrile (CRVIII-35),  
5-(4-Acetoxy-3-methoxyphenyl)-2-benzenesulfonyl-penta-2E,4E-dienenitrile (CRVIII-49)  
20 5-(3,4-Dihydroxyphenyl)-2-(pyridine-2-sulfonyl)-penta-2E,4E-dienenitrile (CRVIII-50),  
2-(4-Chlorobenzenesulfonyl)-5-(3,4-dihydroxyphenyl)-penta-2E,4E-dienenitrile (CRVIII-51),  
5-(3,4-Dihydroxyphenyl)-2-(toluene-4-sulfonyl)-penta-2E,4E-dienenitrile  
25 (CRVIII-52), and  
5-(3,4-Dihydroxyphenyl)-2-methanesulfonyl-penta-2E,4E-dienenitrile (CRVIII-53).
30. A composition comprising a compound according to any one of claims 20 to 29 in admixture with a pharmaceutically acceptable diluent or carrier.


31. A composition comprising, in admixture with a pharmaceutically acceptable diluent or carrier, a compound of Formula IV, or a salt, solvate, or hydrate thereof



wherein

- 5  $R^1$ ,  $R^2$  and  $R^3$  are each independently selected from H, OH,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkylCO<sub>2</sub>, NH<sub>2</sub>, NH- $C_{1-6}$ alkyl, N( $C_{1-6}$ alkyl)( $C_{1-6}$ alkyl),  $C_{1-6}$ alkyl(C=O)NH,  $C_{1-6}$ alkyl(C=O)N( $C_{1-6}$ alkyl), SH, S- $C_{1-6}$ alkyl, NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, and halo; and  $R^4$  is selected from  $C_{1-6}$ alkyl, phenyl and pyridyl, wherein phenyl and pyridyl are unsubstituted or substituted with 1-4 substituents, independently selected from
- 10  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, and halo.

32. A use to prepare a medicament to modulate cell proliferation of a composition according to claim 30 or 31, and/or a compound capable of modulating cell proliferation of Formula IV, and/or a salt, solvate or hydrate thereof:




15 wherein

- $R^1$ ,  $R^2$  and  $R^3$  are each independently selected from H, OH,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkylCO<sub>2</sub>, NH<sub>2</sub>, NH- $C_{1-6}$ alkyl, N( $C_{1-6}$ alkyl)( $C_{1-6}$ alkyl),  $C_{1-6}$ alkyl(C=O)NH,  $C_{1-6}$ alkyl(C=O)N( $C_{1-6}$ alkyl), SH, S- $C_{1-6}$ alkyl, NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, and halo; and  $R^4$  is selected from  $C_{1-6}$ alkyl, phenyl, and pyridyl, wherein phenyl and pyridyl are
- 20 unsubstituted or substituted with 1-4 substituents, independently selected from  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, and halo.

33. The use according to claim 13, for inhibiting cell proliferation.

34. The use according to claim 14 wherein the cell is a malignant hematopoietic cell.

35. A method of modulating cell proliferation comprising administering to a cell or animal in need thereof an effective amount of a composition according to any of claims 30 and 31, and/or a compound capable of modulating cell proliferation of Formula IV, or a salt, solvate or hydrate thereof:



5

wherein

$R^1$ ,  $R^2$  and  $R^3$  are each independently selected from H, OH,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkylCO<sub>2</sub>, NH<sub>2</sub>, NH- $C_{1-6}$ alkyl, N( $C_{1-6}$ alkyl)( $C_{1-6}$ alkyl),  $C_{1-6}$ alkyl(C=O)NH,  $C_{1-6}$ alkyl(C=O)N( $C_{1-6}$ alkyl), SH, S- $C_{1-6}$ alkyl, NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, and halo; and

10  $R^4$  is selected from  $C_{1-6}$ alkyl, phenyl and pyridyl, wherein phenyl and pyridyl are unsubstituted or substituted with 1-4 substituents, independently selected from  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, and halo.

36. The method according to claim 35, for inhibiting cell proliferation.

37. The method according to claim 36, wherein the cell is a malignant

15 hematopoietic cell.